Evidence map›Paper›PMID 25502724›Full record

ArticlePLoS genetics2014

Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease.

Andrea Ganna, Samira Salihovic, Johan Sundström, Corey D Broeckling, Asa K Hedman, Patrik K E Magnusson, Nancy L Pedersen, Anders Larsson, Agneta Siegbahn, Mihkel Zilmer and 5 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLoS genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04117204 (Identifying a Cardiorenal Protective Diet in a Lower-income African American Population With Chronic Kidney Disease at Risk for Cardiovascular Disease.), which is not on this map. Cited by 162 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed, 3 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04117204 nacompletednot on this mapstarted 2019, after this paper: background citation

Identifying a Cardiorenal Protective Diet in a Lower-income African American Population With Chronic Kidney Disease at Risk for Cardiovascular Disease.

TypeinterventionalSponsorBaylor Research InstituteRan2019 to 2020Enrolled101ConditionsChronic Kidney Diseases, Cardiovascular Diseases, HypertensionArmsFruits and Vegetables
3 · Its place in the literature

Who cites it

162 citing papers in PubMed, 3 syntheses or guidelines pooled it, 282 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Observational
  20. Article

102 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Andrea GannaDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Samira SalihovicDepartment of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala, Sweden.
Johan SundströmDepartment of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala, Sweden.
Corey D BroecklingProteomics and Metabolomics Facility, Colorado State University, Fort Collins, Colorado, United States of America.
Asa K HedmanDepartment of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Patrik K E MagnussonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Nancy L PedersenDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Anders LarssonDepartment of Medical Sciences, Biochemial structure and function, Uppsala University, Uppsala, Sweden.
Agneta SiegbahnDepartment of Medical Sciences, Coagulation and inflammation science, Uppsala University, Uppsala, Sweden.
Mihkel ZilmerDepartment of Biochemistry, Centre of Excellence for Translational Medicine, University of Tartu, Tartu, Estonia.
Jessica PrenniProteomics and Metabolomics Facility, Colorado State University, Fort Collins, Colorado, United States of America; Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, Colorado, United States of America.
Johan ArnlövDepartment of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden; School of Health and Social Studies, Dalarna University, Falun, Sweden.
Lars LindDepartment of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala, Sweden.
Tove FallDepartment of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Erik IngelssonDepartment of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
Uppsala University · SEKarolinska Institutet · SEColorado State University · USCentre for Human Genetics · GBDalarna University · SEUniversity of Tartu · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Analyses of circulating metabolites in large prospective epidemiological studies could lead to improved prediction and better biological understanding of coronary heart disease (CHD). We performed a mass spectrometry-based non-targeted metabolomics study for association with incident CHD events in 1,028 individuals (131 events; 10 y. median follow-up) with validation in 1,670 individuals (282 events; 3.9 y. median follow-up). Four metabolites were replicated and independent of main cardiovascular risk factors [lysophosphatidylcholine 18∶1 (hazard ratio [HR] per standard deviation [SD] increment = 0.77, P-value<0.001), lysophosphatidylcholine 18∶2 (HR = 0.81, P-value<0.001), monoglyceride 18∶2 (MG 18∶2; HR = 1.18, P-value = 0.011) and sphingomyelin 28∶1 (HR = 0.85, P-value = 0.015)]. Together they contributed to moderate improvements in discrimination and re-classification in addition to traditional risk factors (C-statistic: 0.76 vs. 0.75; NRI: 9.2%). MG 18∶2 was associated with CHD independently of triglycerides. Lysophosphatidylcholines were negatively associated with body mass index, C-reactive protein and with less evidence of subclinical cardiovascular disease in additional 970 participants; a reverse pattern was observed for MG 18∶2. MG 18∶2 showed an enrichment (P-value = 0.002) of significant associations with CHD-associated SNPs (P-value = 1.2×10-7 for association with rs964184 in the ZNF259/APOA5 region) and a weak, but positive causal effect (odds ratio = 1.05 per SD increment in MG 18∶2, P-value = 0.05) on CHD, as suggested by Mendelian randomization analysis. In conclusion, we identified four lipid-related metabolites with evidence for clinical utility, as well as a causal role in CHD development.

Indexed as

AgedBiomarkersCoronary DiseaseC-Reactive ProteinFemaleFollow-Up StudiesGene Expression ProfilingGenetic Association StudiesHumansIncidenceLinear ModelsLongitudinal StudiesLysophosphatidylcholinesMaleMetabolomicsMiddle AgedBiomarkersC-Reactive ProteinLysophosphatidylcholinesMonoglyceridesSphingomyelins

Identifiers

PMID25502724
PMCPMC4263376
OpenAlexW2143860368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.